MARKER THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $0 | $500.0K | $213.2K | $206.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $11.8M | $13.5M | $10.4M | $12.0M | $27.8M | $18.9M | $12.8M | $8.0M |
| SG&A Expense | $4.2M | $4.2M | $7.5M | $11.3M | $12.9M | $10.5M | $10.0M | $24.4M |
| Operating Income | $-12.9M | $-11.1M | $-14.6M | $-19.8M | $-39.5M | $-28.9M | $-22.5M | $-148.2M |
| Operating Margin | -363.5% | -168.7% | -440.4% | -563.3% | — | -5,777.2% | -10,567.3% | -71,930.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-12.2M | $-10.7M | $-14.0M | $-19.8M | — | — | — | — |
| Income Tax Expense | $-15.2K | $50.0K | $3.7K | — | — | — | — | $0 |
| Net Income | $-12.2M | $-10.7M | $-8.2M | $-29.9M | $-41.9M | $-28.7M | $-21.4M | $-148.0M |
| Net Margin | -343.0% | -162.8% | -248.8% | -851.9% | — | -5,741.2% | -10,050.9% | -71,826.3% |
| EPS (Basic) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-0.61 | $-0.47 | $-3.88 |
| EPS (Diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-0.61 | $-0.47 | $-3.88 |
| Shares Outstanding (Basic) | 15.3M | 9.0M | 8.8M | 8.4M | 7.7M | 47.0M | 45.6M | 38.2M |
| Shares Outstanding (Diluted) | 15.3M | 9.0M | 8.8M | 8.4M | 7.7M | 47.0M | 45.6M | 38.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |